Which has stronger valuation and earnings, AVTR or RVTY?

Revvity has lower revenue, but higher earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avantor $6.55B 1.54 -$530.20M -$0.84 N/A Revvity $2.86B 4.85 $241.20M $2.10 59.07

Is AVTR or RVTY more profitable?

Revvity has a net margin of 8.16% compared to Avantor's net margin of -8.81%. Avantor's return on equity of 9.92% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Avantor -8.81% 9.92% 4.75% Revvity 8.16% 8.34% 5.01%

Does the media prefer AVTR or RVTY?

In the previous week, Revvity had 18 more articles in the media than Avantor. MarketBeat recorded 23 mentions for Revvity and 5 mentions for Avantor. Avantor's average media sentiment score of 1.41 beat Revvity's score of 0.97 indicating that Avantor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avantor 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TMO or AVTR?

In the previous week, Thermo Fisher Scientific had 33 more articles in the media than Avantor. MarketBeat recorded 38 mentions for Thermo Fisher Scientific and 5 mentions for Avantor. Avantor's average media sentiment score of 1.41 beat Thermo Fisher Scientific's score of 1.30 indicating that Avantor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Thermo Fisher Scientific 30 Very Positive mention(s) 6 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avantor 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ILMN or AVTR?

Illumina has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Illumina $4.34B 7.13 $850M $5.36 38.25 Avantor $6.55B 1.54 -$530.20M -$0.84 N/A

Is ILMN or AVTR more profitable?

Illumina has a net margin of 18.36% compared to Avantor's net margin of -8.81%. Illumina's return on equity of 29.84% beat Avantor's return on equity. Company Net Margins Return on Equity Return on Assets Illumina 18.36% 29.84% 12.17% Avantor -8.81% 9.92% 4.75%

Does the media favor ILMN or AVTR?

In the previous week, Illumina had 34 more articles in the media than Avantor. MarketBeat recorded 39 mentions for Illumina and 5 mentions for Avantor. Avantor's average media sentiment score of 1.41 beat Illumina's score of 0.75 indicating that Avantor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 21 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive Avantor 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MTD or AVTR?

In the previous week, Mettler-Toledo International had 8 more articles in the media than Avantor. MarketBeat recorded 13 mentions for Mettler-Toledo International and 5 mentions for Avantor. Avantor's average media sentiment score of 1.41 beat Mettler-Toledo International's score of 1.05 indicating that Avantor is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avantor 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, AVTR or MEDP?

Medpace has lower revenue, but higher earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avantor $6.55B 1.54 -$530.20M -$0.84 N/A Medpace $2.53B 6.47 $451.12M $17.06 34.37

Is AVTR or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Avantor's net margin of -8.81%. Medpace's return on equity of 110.15% beat Avantor's return on equity. Company Net Margins Return on Equity Return on Assets Avantor -8.81% 9.92% 4.75% Medpace 17.67% 110.15% 24.84%

Does the media prefer AVTR or MEDP?

In the previous week, Medpace had 5 more articles in the media than Avantor. MarketBeat recorded 10 mentions for Medpace and 5 mentions for Avantor. Medpace's average media sentiment score of 1.53 beat Avantor's score of 1.41 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avantor 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medpace 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Avantor (AVTR) Competitors

$14.89 -0.36 (-2.36%)

Closing price 09/9/2026 03:59 PM Eastern

Extended Trading

$14.81 -0.08 (-0.54%)

As of 09:19 AM Eastern

Compare

AVTR vs. RVTY, TMO, ILMN, MTD, and MEDP

Should you buy Avantor stock or one of its competitors? Avantor's main competitors and comparable companies include Revvity (RVTY), Thermo Fisher Scientific (TMO), Illumina (ILMN), Mettler-Toledo International (MTD), and Medpace (MEDP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Avantor compare to Revvity?

Avantor (NYSE:AVTR) and Revvity (NYSE:RVTY) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Avantor has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Revvity has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

In the previous week, Revvity had 18 more articles in the media than Avantor. MarketBeat recorded 23 mentions for Revvity and 5 mentions for Avantor. Avantor's average media sentiment score of 1.41 beat Revvity's score of 0.97 indicating that Avantor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avantor	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.1% of Avantor shares are owned by institutional investors. Comparatively, 86.7% of Revvity shares are owned by institutional investors. 0.3% of Avantor shares are owned by insiders. Comparatively, 0.9% of Revvity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Avantor currently has a consensus price target of $12.47, indicating a potential downside of 16.25%. Revvity has a consensus price target of $116.57, indicating a potential downside of 6.03%. Given Revvity's stronger consensus rating and higher possible upside, analysts clearly believe Revvity is more favorable than Avantor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avantor	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Revvity has lower revenue, but higher earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avantor	$6.55B	1.54	-$530.20M	-$0.84	N/A
Revvity	$2.86B	4.85	$241.20M	$2.10	59.07

Revvity has a net margin of 8.16% compared to Avantor's net margin of -8.81%. Avantor's return on equity of 9.92% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avantor	-8.81%	9.92%	4.75%
Revvity	8.16%	8.34%	5.01%

Summary

Revvity beats Avantor on 12 of the 16 factors compared between the two stocks.

How does Avantor compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Avantor (NYSE:AVTR) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Thermo Fisher Scientific presently has a consensus price target of $624.64, suggesting a potential upside of 2.87%. Avantor has a consensus price target of $12.47, suggesting a potential downside of 16.25%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, equities analysts clearly believe Thermo Fisher Scientific is more favorable than Avantor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	2 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.73
Avantor	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

In the previous week, Thermo Fisher Scientific had 33 more articles in the media than Avantor. MarketBeat recorded 38 mentions for Thermo Fisher Scientific and 5 mentions for Avantor. Avantor's average media sentiment score of 1.41 beat Thermo Fisher Scientific's score of 1.30 indicating that Avantor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	30 Very Positive mention(s)	6 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avantor	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Avantor has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market.

Thermo Fisher Scientific has higher revenue and earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	5.04	$6.70B	$18.59	32.66
Avantor	$6.55B	1.54	-$530.20M	-$0.84	N/A

Thermo Fisher Scientific has a net margin of 15.04% compared to Avantor's net margin of -8.81%. Thermo Fisher Scientific's return on equity of 17.09% beat Avantor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.04%	17.09%	8.12%
Avantor	-8.81%	9.92%	4.75%

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Comparatively, 0.3% of Avantor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Thermo Fisher Scientific beats Avantor on 14 of the 17 factors compared between the two stocks.

How does Avantor compare to Illumina?

Illumina (NASDAQ:ILMN) and Avantor (NYSE:AVTR) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

89.4% of Illumina shares are owned by institutional investors. Comparatively, 95.1% of Avantor shares are owned by institutional investors. 2.9% of Illumina shares are owned by insiders. Comparatively, 0.3% of Avantor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Illumina has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Avantor has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

In the previous week, Illumina had 34 more articles in the media than Avantor. MarketBeat recorded 39 mentions for Illumina and 5 mentions for Avantor. Avantor's average media sentiment score of 1.41 beat Illumina's score of 0.75 indicating that Avantor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	21 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
Avantor	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Illumina currently has a consensus target price of $199.13, indicating a potential downside of 2.87%. Avantor has a consensus target price of $12.47, indicating a potential downside of 16.25%. Given Illumina's stronger consensus rating and higher possible upside, equities analysts clearly believe Illumina is more favorable than Avantor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44
Avantor	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Illumina has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	7.13	$850M	$5.36	38.25
Avantor	$6.55B	1.54	-$530.20M	-$0.84	N/A

Illumina has a net margin of 18.36% compared to Avantor's net margin of -8.81%. Illumina's return on equity of 29.84% beat Avantor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Avantor	-8.81%	9.92%	4.75%

Summary

Illumina beats Avantor on 13 of the 16 factors compared between the two stocks.

How does Avantor compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Avantor (NYSE:AVTR) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Mettler-Toledo International had 8 more articles in the media than Avantor. MarketBeat recorded 13 mentions for Mettler-Toledo International and 5 mentions for Avantor. Avantor's average media sentiment score of 1.41 beat Mettler-Toledo International's score of 1.05 indicating that Avantor is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avantor	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mettler-Toledo International has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Avantor has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Mettler-Toledo International presently has a consensus price target of $1,446.36, indicating a potential upside of 12.02%. Avantor has a consensus price target of $12.47, indicating a potential downside of 16.25%. Given Mettler-Toledo International's stronger consensus rating and higher probable upside, equities analysts plainly believe Mettler-Toledo International is more favorable than Avantor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.31
Avantor	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06

Mettler-Toledo International has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03B	6.43	$869.19M	$44.43	29.06
Avantor	$6.55B	1.54	-$530.20M	-$0.84	N/A

Mettler-Toledo International has a net margin of 21.91% compared to Avantor's net margin of -8.81%. Avantor's return on equity of 9.92% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Avantor	-8.81%	9.92%	4.75%

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 95.1% of Avantor shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 0.3% of Avantor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Mettler-Toledo International beats Avantor on 12 of the 16 factors compared between the two stocks.

How does Avantor compare to Medpace?

Avantor (NYSE:AVTR) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Avantor has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Medpace has a net margin of 17.67% compared to Avantor's net margin of -8.81%. Medpace's return on equity of 110.15% beat Avantor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avantor	-8.81%	9.92%	4.75%
Medpace	17.67%	110.15%	24.84%

Medpace has lower revenue, but higher earnings than Avantor. Avantor is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avantor	$6.55B	1.54	-$530.20M	-$0.84	N/A
Medpace	$2.53B	6.47	$451.12M	$17.06	34.37

In the previous week, Medpace had 5 more articles in the media than Avantor. MarketBeat recorded 10 mentions for Medpace and 5 mentions for Avantor. Medpace's average media sentiment score of 1.53 beat Avantor's score of 1.41 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avantor	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medpace	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Avantor currently has a consensus target price of $12.47, indicating a potential downside of 16.25%. Medpace has a consensus target price of $595.20, indicating a potential upside of 1.52%. Given Medpace's stronger consensus rating and higher possible upside, analysts clearly believe Medpace is more favorable than Avantor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avantor	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06
Medpace	0 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

95.1% of Avantor shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.3% of Avantor shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Medpace beats Avantor on 14 of the 16 factors compared between the two stocks.

Get Avantor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTR vs. The Competition

Export

Metric	Avantor	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$10.31B	$9.79B	$7.22B	$23.49B
Dividend Yield	N/A	1.47%	2.55%	3.76%
P/E Ratio	-17.73	65.14	271.78	28.73
Price / Sales	1.54	109.33	710.80	20.77
Price / Cash	10.07	26.46	77.55	34.36
Price / Book	1.82	5.25	10.53	4.74
Net Income	-$530.20M	$56.67B	$3.48B	$1.07B
7 Day Performance	-1.85%	-1.25%	-1.16%	-1.48%
1 Month Performance	8.53%	0.13%	2.01%	-2.03%
1 Year Performance	17.94%	26.04%	21.91%	11.67%

Avantor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTR Avantor	1.5391 of 5 stars	$14.89 -2.4%	$12.47 -16.2%	+15.7%	$10.31B	$6.55B	N/A	13,500	Positive News Analyst Forecast
RVTY Revvity	3.2204 of 5 stars	$128.76 0.0%	$108.36 -15.8%	+45.8%	$14.37B	$2.86B	61.31	11,000	Trending News Analyst Forecast Analyst Revision
TMO Thermo Fisher Scientific	4.2253 of 5 stars	$618.83 -0.5%	$619.41 +0.1%	+25.5%	$230.05B	$44.56B	33.29	125,000	Positive News Analyst Upgrade
ILMN Illumina	2.2327 of 5 stars	$213.63 -0.9%	$188.40 -11.8%	+108.7%	$32.55B	$4.34B	39.86	8,650	Analyst Forecast
MTD Mettler-Toledo International	4.1369 of 5 stars	$1,405.98 +0.5%	$1,461.27 +3.9%	+0.4%	$28.02B	$4.03B	31.64	18,100	Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:AVTR) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avantor (AVTR) Competitors